Article: What challenges does the advanced therapies sector face?
Summary: Drug Discovery World’s Megan Thomas heard from Philip Wills, Ph.D., Chief Commercial Officer, Catalent Cell & Gene Therapy, as well as other attendees at ATW 2024 about the obstacles the sector needs to overcome to succeed. Catalent commented on pricing and approval of advanced therapies. Read the full article today.
KEY LEARNINGS:
- Pricing of advanced therapies requires innovative thinking
- Philip Wills responds, “The industry, as a whole, needs to carefully consider the true value of curing lifelong genetic or degenerative diseases, particularly when evaluating novel therapeutics that present unique treatment opportunities.”
- Other attendees provide insights across various topics